OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
January 29, 2025
Host Jonathan Miller interviews CEO: Ram Mukunda, who shows us how the company is pushing the boundaries of scientific discovery, creating life-changing medications, and improving the quality of life for individuals around the globe.
January 29, 2025
January 14, 2025
July 16, 2024
July 9, 2024